Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Robert T. Brodell MD, FAAD Editor-in-Chief

See All Experts

featured

Published in Dermatology

Journal Scan / Research · October 29, 2024

Outcomes of Treatment With Upadacitinib Over 1 Month Among Patients With Moderate to Severe Atopic Dermatitis

Dermatitis

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

J. Albrecht MD

Thy Huynh MD, FAAD

Dermatitis

Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study

Dermatitis 2024 Oct 03;[EPub Ahead of Print], E Pezzolo, M Napolitano, A Narcisi, L Gargiulo, I Trave, M Rossi, R Satta, F Caroppo, R Pandolfi, A Guglielmo, K Nan, C Patruno, L Naldi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Outcomes of Treatment With Upadacitinib Over 1 Month Among Patients With Moderate to Severe Atopic Dermatitis

Additional Info

Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study

Further Reading

Final Note From the Dermatology Editors

Outcomes of Treatment With 5-Fluorouracil 5% Cream in Patients With Squamous Cell Carcinoma In Situ

Outcomes of Field-Directed Photodynamic Therapy Using BF-200 ALA in Patients With Actinic Keratosis

Patient Preferences Regarding the Treatment of Bowen's Disease

Cost-Utility Analysis of Clinic-Based Deroofing vs Local Excision for Hidradenitis Suppurativa

Assessing the Strategies Used to Improve Patient Diversity in a Novel Psoriasis Study

Clinical Presentation, Diagnosis, and Management of Drug Reaction With Eosinophilia and Systemic Symptoms

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Recently Updated